ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

TNXP Tonix Pharmaceuticals Holding Corporation

0.133
-0.007 (-5.00%)
16 Nov 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Tonix Pharmaceuticals Holding Corporation NASDAQ:TNXP NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.007 -5.00% 0.133 0.1315 0.1331 0.1402 0.1286 0.1401 10,351,066 00:59:27

Form 424B5 - Prospectus [Rule 424(b)(5)]

30/08/2024 10:04pm

Edgar (US Regulatory)


 

Filed Pursuant to Rule 424(b)(5)
Registration No. 333-266982

 

PROSPECTUS SUPPLEMENT

 

(To Prospectus Dated July 30, 2024)

 

$150,000,000

 

 

 

Common Stock

 

 

This prospectus supplement amends and supplements the information in the prospectus, dated July 30, 2024, filed as a part of our registration statement on Form S-3 (File No. 333-266982), or the Prior Prospectus. This prospectus supplement should be read in conjunction with the Prior Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prior Prospectus. This prospectus supplement is not complete without, and may only be delivered or utilized in connection with, the Prior Prospectus, and any future amendments or supplements thereto.

 

Under the Prior Prospectus, we registered up to $50,000,000 of our Common Stock, $0.001 par value per share, for offer and sale pursuant to a Sales Agreement, dated July 30, 2024, or the Sales Agreement, between us and A.G.P./Alliance Global Partners. From July 30, 2024 through the date of this prospectus supplement, we sold an aggregate of 81,957,296 shares of our Common Stock for an aggregate purchase price of $34.9 million under the Prior Prospectus. As of the date of this prospectus supplement, we are increasing the aggregate amount of Common Stock that we are offering pursuant to the Sales Agreement, such that we are offering up to an aggregate of $150,000,000 of our Common Stock for sale under the Sales Agreement, including the shares of Common Stock previously sold, or $115.1 million from and after the date hereof.

  

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.

 

A.G.P.

 

The date of this prospectus supplement is August 30, 2024. 

 

 

 


1 Year Tonix Pharmaceuticals Chart

1 Year Tonix Pharmaceuticals Chart

1 Month Tonix Pharmaceuticals Chart

1 Month Tonix Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock